Updates are available Correction dated 2025-08-01
Click to view Correction: https://doi.org/10.1007/s00415-025-13122-z
-
Authors
Ferreira, Joaquim J. https://orcid.org/0000-0003-3950-5113
Lee, Jee-Young
Ma, Hyeo-il
Jeon, Beomseok
Poewe, Werner
Antonini, Angelo
Stocchi, Fabrizio
Rodrigues, Daniela M.
Fonseca, Miguel M.
Castilla-Fernández, Guillermo
Holenz, Joerg
Rocha, José-Francisco
Rascol, Olivier
,
-
Funding
Funding for this research was provided by:
BIAL
Unidade Local de Saúde de São José
- License Information
-
More Information
Article History
Received: 13 May 2024
Revised: 25 July 2024
Accepted: 28 July 2024
First Online: 21 August 2024
Change Date: 1 August 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00415-025-13122-z
Declarations
:
: Joaquim J. Ferreira has provided consultancy and received speaker fees from Lundbeck, BIAL, Biogen, Acadia, Abbvie, Sunovion Pharmaceuticals, Zambon, Affiris, Roche, ONO and SK Chemicals and has received grants from Abbvie, Bial, Medtronic and Angelini. Jee-Young Lee received a research grant of NRF funded by the MSIT of Korea and a multidisciplinary research grant-in-aid and a focused clinical research grant-in-aid from the Seoul Metropolitan Government-Seoul National University (SMG-SNU) Boramae Medical Center, and speaker honorarium from Esai Korea, Bial, SK chemicals and Scientific Advisory Board of Regeners Inc. Beomseok Jeon has received research grant from Peptron and Abbvie Korea and has participated in an expert panel for Aspen Neuroscience. Werner Poewe has received lecture fees and honoraria for consultancy in relation to clinical drug development programs from Alterity, AbbVie, Affiris, AstraZeneca, Axovant, BIAL, Biogen, Britannia, Lilly, Lundbeck, NeuroDerm, Neurocrine, Denali Pharmaceuticals, Orion Pharma, Roche, Stada, Sunovion, Takeda, UCB and Zambon, as well as grant support from the MJFF and the EU FP7 & Horizon 2020 programs. Angelo Antonini has received compensation for consultancy and speaker-related activities from UCB, Boehringer Ingelheim, Britannia, AbbVie, Zambon, Bial, NeuroDerm, Theravance Biopharma, Roche; he receives research support from Chiesi Pharmaceuticals, Lundbeck, Horizon 2020 - Grant 825785, Horizon2020 Grant 101016902, Ministry of Education University and Research (MIUR) Grant ARS01_01081, Cariparo Foundation. He serves as consultant for Boehringer Ingelheim for legal cases on pathological gambling; owns Patent WO2015110261-A1; and owns shares in PD Neurotechnology Limited. Fabrizio Stocchi has received compensation for consultancy and speaker related activities from Lundbeck, UCB, Chiesi, Zambon, Britannia, Cynapsus, Sunovion, Kyowa, Abbvie, NeuroDerm, Biogen, Bial. Daniela M. Rodrigues, Miguel M. Fonseca, Guillermo Castilla-Fernández, Joerg Holenz and José-Francisco Rocha are employed by BIAL. Olivier Rascol has participated in advisory boards and/or provided consultancy for AbbVie, Adamas, Acorda, Addex, AlzProtect, ApoPharma, AstraZeneca, Axovant, Bial, Biogen, Britannia, Buckwang, CereSpir, Clevexel, Denali, INC Research, IPMDS, Lundbeck, Lupin, Merck, MundiPharma, NeurATRIS, NeuroDerm, Novartis, ONO Pharma, Osmotica, Parexel, Pfizer, Prexton Therapeutics, Quintiles, Roche, Sanofi, Servier, Sunovion, Theranexus, Takeda, Teva, UCB, Vectura, Watermark Research, XenoPort, XO, Zambon; received grants from Agence Nationale de la Recherche (ANR), CHU de Toulouse, France-Parkinson, INSERM-DHOS Recherche Clinique Translationnelle, MJ Fox Foundation, Programme Hospitalier de Recherche Clinique, European Commission (FP7, H2020), Cure Parkinson UK; and received a grant to participate in a symposium and contribute to the review of an article by the International Parkinson and Movement Disorder Society.
